富田製薬株式会社

The founder, Kyuzaburo Tomita, began full-scale research in Shizuoka on a manufacturing process using bittern as a raw material. His goal was to mass-produce magnesium carbonate for pharmaceutical use at good quality and low cost, hopeful to make it as a replacement for imported expensive products.

In the same year, he started manufacturing and selling cough medicine “Lauryl Sulfate Water” and “Lauryl Oil” from the Japanese evergreen oak, and invests all of the profits from the sales in researching the manufacturing process of magnesium carbonate.

創業者の富田久三郎は、当時、高価な海外輸入品に頼っていた医薬用途の炭酸マグネシウムを良質で安価に量産するため、苦汁を原料とする製法の本格的な研究を静岡で始める。

同年、大葉樫から咳止め薬「ローリルケルス水」、「ローリル油」の製造販売するが、その売上利益の全てを炭酸マグネシウムの製法研究へ投資。

Moved in Shizuoka Prefecture in order to continue to procure bittern. He also began research into sodium carbonate, the main raw material for magnesium carbonate.

After repeated failures, they achieved the creation of magnesium carbonate, but it had less bulk than the intended result. The company attempted to market this product as “heavy magnesium carbonate” but it was not accepted in a market.

苦汁調達のため、静岡県内を転居する。また、主原料となる炭酸ソーダの研究にも取り組む。

失敗を重ね出来上がった炭酸マグネシウムは目的としたものとは異なり、嵩が低いものであった。「重質炭酸マグネシア」として販売するも市場には受け入れられなかった。

Pure magnesium carbonate production was at last achieved after thorough review of the manufacturing process and development of equipments. Acetic acid, sulfuric acid, nitric acid, ether, and other chemicals and also under production.

製法の見直し、機械・装置の開発により、待望の純良品の炭酸マグネシウム製法を完成。酢酸・硫酸・硝酸・エーテルなども製造。

Kyuzaburo (age 28) went to the Jishu salt fields (near the Seto Inland Sea) in search of a large amount of bittern. At that time, in the Jishu salt fields, after salt was extracted from seawater, the remaining bittern was discarded into the sea.

The factory operation in Kiga, Shizuoka failed in mass production and was closed, but the business and research continued.

久三郎（28歳）は、大量の苦汁を求め十州塩田（瀬戸内海近辺）へ調査に出向く。当時の十州塩田地方では、海水から食塩を採取後、残った苦汁を海中に投棄していた。

静岡（気賀）の工場経営は量産に失敗し閉鎖するも、事業と研究は継続。

Magnesium carbonate became official for British Pharmacopoeia and ether became officlal for US Pharmacopeia.

炭酸マグネシウムは英国局方、エーテルは米国局方を取得。

苦汁確保のため、静岡県（浜名）に天日製塩の施設を作り事業を開始するも、事業に必要な土地の確保、塩の価格暴落が本業の製薬業へ影響したため、中止。

The Japanese Pharmacopoeia was enacted and promulgated (and went into effect the following year), and magnesium carbonate and magnesium sulfate were approved. It was touted that “the only domestic products that conformed to the pharmacopoeia were Tomita’s products.”

The credibility of the trademark “Ⓣ” mark increased, and demand for the product increased day by day. After years of struggling financially, Tomita was able to turn a profit.

Years later, Kyuzaburo was quoted as saying, “The heavens did not abandon the struggling man, but gave him a great boon. What was this boon? It was the enactment of the Japanese Pharmacopoeia in June of 1887.”

日本薬局方が制定公布（翌年施行）され、炭酸マグネシウム・硫酸マグネシウムが合格。「薬局方に適合したもののうち、国産品は富田の製品のみである」と賛辞を受けた。

富田製薬の商標であるⓉ印の信用は高まり、需要は日増しに増加。多年にわたる窮乏を盛り返し、利益を得る。

後年の久三郎曰く、「天は苦心者を捨て給わず、果然一大恩恵を与えてくれた。恩恵とは何ぞや、それこそ明治19年6月に実施せられた日本薬局方の制定である。」

Just as the business was beginning to take off, the factory burnt down in a fire. The company lost not only its machinery but also all of its research materials, and had no choice but to cease operations.

事業が軌道に乗り始めた矢先、工場が全焼。機械だけでなく研究資料等も全て失い、事業中止。

Re-examined the Jishu salt fields in the Setouchi area. Reached the conclusion that establishing a pharmaceutical plant in the Jishu salt fields would be an efficient way to secure bittern.

十州塩田を再調査。十州塩田地方に製薬工場を設置することにより効率的に苦汁を確保できるとの結論に至る。

Succeeded in separating and producing potassium chloride from bittern for the first time in Japan.

日本で初めて苦汁中の塩化カリウムの分離製造に成功。

Kyuzaburo moved to Naruto, Tokushima Prefecture and built a factory in Seto-Cho (now Naruto City).

久三郎は徳島県鳴門に移り住み、現：鳴門市瀬戸町に工場を建設。

「富田海産塩類製造所」を設立。炭酸マグネシウム、硫酸マグネシウムの本格的な生産を開始。

Tomita Marine Products Industry was established on January 1. Full-scale production of magnesium carbonate and magnesium sulfate began.

Participates in the 4th National industrial Exhibition held in Kyoto. Here, Tomita showcased their magnesium carbonate, magnesium carbonate(heavy), magnesium sulfide, magnesium sulfate, potassium iodide, potassium bromide, sodium bromide, and sodium chloride.

A stone oven was used to extract salt from soil by boiling seawater in stone cauldrons. The salt was refined by removing the sodium sulfate contained within. It was named “Japanese salt” and sold.

The name of the company was changed to Tomita Pharmaceutical Factory.

Succeeded in separating and producing potassium chloride from bittern whose demand was increased due to Japan’s supply shortage after WWI.

第一次世界大戦下における国の物資調達不足を背景とし、需要の高まった塩化カリウムの苦汁中からの分離、製造に成功する。

Started focusing on the poduction of magnesium carbonate, potassium chloride, and bromine by reorganizing products line-up and establishing a new factory.

製品の改編、工場設立により炭酸マグネシウム、塩化カリウム、臭素の製造に注力する。

ゴム工業発展による炭酸マグネシウムの需要増加に応えつつ、透明ゴム加工用炭酸マグネシウムの製造に成功。

After WWI, the production of sodium chloride, which was rapidly in short supply, was started with the permission of recrystallized salt production.

第一次世界大戦以降、急速な品不足となった局方塩化ナトリウムを再製塩製造の許可を得て製造開始。（特殊許可1号）

The invention of the concrete assembly-type Numai-dai (swamp well platform) contributed to the improvement of salt manufacturing technology in the Irihama typesalt fields*, and a subsidy was granted to the company for promoting the propagationand industrial development of the industry.

考案したコンクリート製の組立式沼井台が、入浜式塩田における製塩技術の向上に寄与し、殖産興業助成が交付される。

Kyuzaburo (age 76) left for an 8-month tour of Germany for pharmaceutical research.

久三郎が薬学研究のため、8カ月の西洋視察（ドイツ）へ出発。久三郎（76歳）。

In response to the postwar recession, Kyuzaburo researched magnesium carbonate manufacturing methods. He succeeded in the industrialization of a manufacturing method of utilizing caustic lime as a starting material, and also perfected the manufacturing method for magnesium oxide.

第一次世界大戦後の不況を受け、炭酸マグネシウムの製法を研究。石灰式製法の工業化に成功し、酸化マグネシウムの製法も完成させる。

Tomita Pharmaceutical Factory was reorganized into a corporation and establishes itself as Tomita Seiyakusho Co.,Ltd.

富田製薬工場を法人組織に改組し、「株式会社富田製薬所」を設立。

Sales of the health conditioning agent Robaston.

Responding to the issuance of the “Order for Control of Daily Necessities,” the product of “bittern potassium salt” was sold as a fertilizer. Production was discontinued three years later due to Strategic Industries Control Act of the bittern industry.

A ceremony commemorating Tomita’s 50th anniversary was held at the newly renovated magnesium sulfate plant.

Received an order from the Navy to produce strontium.

海軍よりストロンチウムの生産命令を受ける。

The company began marketing vaccines for oral dysentery, typhoid, and paratyphoid, as well as an injectable vitamin B2 and the prophylactic drug penicillin.

The four large chimneys that had served as a symbol of the company were removed from its building during the war for fear that they would be used as air raid markers.

内服用赤痢ワクチン、チフスワクチン、パラチフスワクチンの他、注射用ビタミンB2、予防薬ペニシリンを販売。

会社のシンボルであった4本の大煙突は、戦時下において空襲の目印になるとの危惧から撤去。

富田貞三郎を代表取締役とした「富田製薬株式会社」を設立。

The Nankai Earthquake in 1946.

In 1947, the company began marketing “Macron tablets,” an anthelmintic with an active ingredient of seaweed extract.

A fire at a magnesium carbonate drying plant in 1948.

Using by-products from textile mills, the company began producing anhydrous sodium sulfate in 1949.

A fire at a salt brine refinery in 1949.

Typhoon Jane in 1950.

During this five-year period, the company researched and developed a wide range of products for which it was licensed to manufacture, including barium chloride, camphor oil injection, barium sulfate, Ringer’s solution, saline solution, vitamin B2 injection solution, and saline tablets.

Using by-products from textile mills, the company began producing sodium sulfide in 1951.

Tomita Pharmaceutical Co., Ltd. was established on July 8 (using the current Japanese name), with Teizaburo Tomita as representative director.

The company was affected by the bankruptcy of its main customers and the resulting dishonored check. Even during the high-growth period of the Japanese economy, Tomita’s business conditions remained tense.

As a challenge in a new field, the company developed and sold an organic hair straightening agent, “Ammonium Thioglycolate.”

Magnesium silicate was developed and marketed as an antacid.

Developed high-purity magnesium oxide for silicon steel sheets.

Suffered severe damage from the second Muroto typhoon. Production of “Ammonium Thioglycolate” was discontinued due to damage to the manufacturing equipment caused by the second Muroto Typhoon.

Started trade with Korea and Taiwan.

The company developed aluminum hydroxide gel and synthetic aluminum silicate in order to enter the field of antacid agents in earnest.

Developed magnesium metasilicate aluminate as an antacid agent.

Started trade with Hong Kong, Vietnam, the Philippines, and Australia.

Management policy was formulated into a long-term plan under the guidance of Tanabe Management Counseling Center. Established “Company Policy,” “Creed,” and “Corporate Mission Statement.” A management policy presentation meeting was held, and the corporate structure was enhanced and improved.

Developed “Wakame Tea” using wakame seaweed, a specialty of Naruto City, and registered it as a trademark. However, the market response was weak and the company abandoned the commercialization of the product.

Succeeded in developing high-purity Sodium Chloride for use in artificial dialysis.

Developed and began sale of Uni-Meisui, a natural liquor clarifier made from carrageenan.

Established Tokushima Plant in Tokushima Pharmaceutical Industrial Park to strengthen facilities to meet increasing demand for antacids.

With the enactment of the “Pharmaceutical GMP” ministerial ordinance, the company worked to estabilish a quality system from the point of both management system and equipment control.

Research was initiated on the production of gluconic acid from mold fungi.

Started joint research with the Agency of Industrial Science and Technology and the Shikoku National Industrial Research Institute on pore size control technology for inorganic salts.

Started production and sale of the synthetic adsorbent TOMIX-AD and high-performance adsorbent Q-Fine series.

Tomita was contracted to produce powdered artificial seawater “Marine Art” in collaboration with Senju Pharmaceutical Co., Ltd.

Celebrated 100 years of business.

創業100年を迎える。

Mass production of a powdered dialysate for overseas markets began.

粉末透析剤を海外向けに量産化。

The first powdered dialysate production facility was completed.

Full-scale production began.

粉末透析剤1号棟完成。

粉末透析剤製造へ本格稼働。

Launched sales of powdered dialysate KIDOLIME T-30.

粉末透析剤「キドライムT-30」を販売開始。

A second powdered dialysate production facility was completed.

A system to increase production was established.

粉末透析剤2号棟完成。

粉末透析剤製造への増産体制構築。

Began operation of the Kawasaki Plant, a plant dedicated to the production of sodium chloride.

Completion of magnesium oxide production building.

塩化ナトリウム製造専用工場となる川崎工場の操業を開始。

酸化マグネシウム製造棟完成。

Opened a representative office in New Jersey, USA.

Completion of a manufacturing plant dedicated to the production of FLORITE®.

米国ニュージャージー駐在事務所開設。

フローライト専用製造工場完成。

Tomita R&D Center was completed. Tomita focused on the development of new products as an R&D-oriented company.

Tomita　R&Dセンター完成。研究開発型企業として新製品開発に注力。

A third powdered dialysate production facility was completed.

粉末透析剤3号棟完成。

Compliance Policy and Action Guidelines were established, as well as the Compliance Committee.

コンプライアンス基本方針および行動指針制定。

コンプライアンス委員会を発足。

A new QC center was established, strengthening sales of pharmaceutical raw materials to overseas customers.

QCセンターを新設し、海外向け医薬品原料販売を強化。

Quality Policy was established.

品質方針を制定。

法令の遵守と品質最優先のモノづくりに取り組む。